The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.
Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback